乳腺癌前哨淋巴结活检术的研究历程及探索

郭 丰震1, 史 立波2, 陈 呈2, 张 斌3
1、承德医学院
2、沧州市人民医院
3、海兴县医院

摘要


前哨淋巴结活检（SLNB）是当前临床淋巴结阴性早期乳腺癌的标准手术方式，但约80%患者术后病理证实无淋巴结转移，因此筛选可豁免SLNB的患者成为临床关键问题。本文系统梳理乳腺癌前哨淋巴结活检术的发展脉络、临床应用场景及豁免手术的研究进展，聚焦腋窝管理的精准化发展方向，为乳腺癌患者治疗方案的个体化选择提供参考，核心在于平衡治疗有效性与患者生活质量，探索更精准的腋窝管理策略。

关键词


早期乳腺癌；腋窝淋巴结阴性；前哨淋巴结活检；豁免手术

全文:

PDF


参考


[1]Freddie Bray;Mathieu Laversanne;Hyuna Sung;Jacques Ferlay;Rebecca L Siegel;Isabelle Soerjomataram;Ahmedin Jemal.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.[J].CA: a cancer journal for clinicians,2024,74(3).

[2]梁燕,姜军.乳腺癌的区域外科治疗[J].中国普外基础与临床杂志,2019,26(12):1398-1402.

[3]邬思雨,李俊杰,邵志敏.乳腺癌前哨淋巴结活检术的发展历史及研究进展[J].中国癌症杂志,2023,33 (6):551-559.

[4]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2023年版）[J].中国癌症杂志,2023,31(10):954-1040.

[5]Gradishar W J, Moran M S, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20(6): 691-722.

[6]Thompson Jessica L;Wright G Paul.Contemporary approaches to the axilla in breast cancer.[J].American journal of surgery,2022,225(3).

[7]Simons J M, van Nijnatten T J A, van der Pol C C, et al. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer[J]. JAMA surgery, 2022, 157(11): 991-999.

[8]Wu S Y, Li J W, Zhang Y, et al. Repeated core needle biopsy and targeted fine-needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: prospective clinical study[J]. The British Journal of Surgery, 2023, 110(10): 1264-1266.

[9] Burstein H J,Curigliano G, Loibl S,et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019[J].Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019, 30(10): 1541-1557.

[10] Tadros A B,Yang W T,Krishnamurthy S,et al. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery[J]. JAMA surgery, 2017,152(7):665-670.

[11] BARRON A U,HOSKIN T L,DAY C N,et al .Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy[J]. JAMA Surg, 2018,153(12):1120.

[12] Fayanju O M,Ren Y,Thomas S M,et al.The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)[J]. Annals of Surgery, 2018,268(4):591-601.

[13] Pfob A,Sidey-Gibbons C,Rauch G,et al. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0)After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2022,40(17):1903-1915.


Refbacks

  • 当前没有refback。